clinical trial · NCT07486713
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
AML (Acute Myeloid Leukemia)GliomaCholangiocarcinomaSolid Tumor MalignanciesOlutasidenibCYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Probe Substrates
brief summary
A open-label drug-drug interaction (DDI) study to evaluate the effects of olutasidenib on the pharmacokinetics (PK) of a CYP450 and OATP1B1 probe substrate cocktail in participants with IDH1 mutation-positive malignancies.
started
Feb 23, 2026
primary completion
Apr 30, 2027
completion
Jun 30, 2027
last updated
Mar 20, 2026
official title
A Multi-Center, Open-Label, Drug-Drug Interaction Study to Evaluate the Effect of Olutasidenib on the Pharmacokinetics of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Substrates in Patients With IDH1 Mutation-Positive Malignancies Being Treated With Olutasidenib
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol